Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas

Histopathology

Volumn 57, Issue 6, 2010, Pages 862-876

  González, Luis O ^a,b   González Reyes, Salomé ^a,b   Marín, Laura ^a,b   González, Lucía ^a,b   González, José M ^a   Lamelas, Maria L ^a   Merino, Antonio M ^c   Rodríguez, Elena ^a   Pidal, Iván ^a   Del Casar, José M ^a,b   Andicoechea, Alejandro ^a,b   Vizoso, Francisco ^a,b  

^a HOSPITAL DE JOVE   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Inflammation; Leucocytes; MMP; Peritumour stroma; TIMP; Tumour heterogeneity

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHI-SQUARE DISTRIBUTION; CLUSTER ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROGNOSIS; STROMAL CELLS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 78650256036     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03723.x     Document Type: Article

References (37)

1. Johnson JP, Riethmuller G, Schirrmacher V. Tumor immunology: Paul Ehrlich's heritage. Immunol. Today 1989; 10; S35-S37.
2. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br. J. Cancer 2004; 90; 2053-2058.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420; 860-867.
4. Daniel D, Chiu C, Giraudo E et al. CD4 + T cell- mediated antigen- specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005; 65; 2018-2025.
5. Adams TE, Alpert S, Hanahan D. Non- tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 1987; 325; 223-228.
6. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007; 117; 1155-1166.
7. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004; 4; 540-550.
8. Le Bitoux MA, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem. Cell Biol. 2008; 130; 1079-1090.
9. Bingle L, Brown NJ, Lewis CE. The role of tumour- associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002; 196; 254-265.
10. Taskinen M, Karjalainen- Lindsberg ML, Leppa S. Prognostic influence of tumor- infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008; 111; 4664-4667.
11. Nonomura N, Takayama H, Nishimura K et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br. J. Cancer 2007; 97; 952-956.
12. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found. Symp. 2004; 256; 158-168; discussion 168-172, 259-169.
13. Canevari S, Pupa SM, Menard S. 1975-1995 revised anti- cancer serological response: biological significance and clinical implications. Ann. Oncol. 1996; 7; 227-232.
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2; 161-174.
15. Noe V, Fingleton B, Jacobs K et al. Release of an invasion promoter E- cadherin fragment by matrilysin and stromelysin- 1. J. Cell Sci. 2001; 114; 111-118.
16. Manes S, Llorente M, Lacalle RA et al. The matrix metalloproteinase- 9 regulates the insulin- like growth factor- triggered autocrine response in DU- 145 carcinoma cells. J. Biol. Chem. 1999; 274; 6935-6945.
17. Fingleton B, Vargo- Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP- 7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001; 3; 459-468.
18. Stetler- Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 1999; 103; 1237-1241.
19. Cornelius LA, Nehring LC, Harding E et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 1998; 161; 6845-6852.
20. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21; 2245-2252.
21. Wurtz SO, Schrohl AS, Sorensen NM et al. Tissue inhibitor of metalloproteinases- 1 in breast cancer. Endocr. Relat. Cancer 2005; 12; 215-227.
22. Gonzalez LO, Pidal I, Junquera S et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br. J. Cancer 2007; 97; 957-963.
23. Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: vascular growth and survival. APMIS 2004; 112; 431-440.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 2005; 23; 9067-9072.
25. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
26. Parker RL, Huntsman DG, Lesack DW et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am. J. Clin. Pathol. 2002; 117; 723-728.
27. Gonzalez L, Corte MD, Vazquez J et al. Study of matrix metalloproteinases and their tissular inhibitors in ductal in situ carcinomas of the breast. Histopathology 2008; 53; 403-415.
28. Gonzalez LO, Corte MD, Junquera S et al. Expression and prognostic significance of metalloproteases and their inhibitors in both luminal and basal- like phenotypes of breast carcinomas. Hum. Pathol. 2009; 40; 1224-1233.
29. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome- wide expression patterns. Proc. Natl Acad. Sci. USA 1998; 95; 14863-14868.
30. Vizoso FJ, Gonzalez LO, Corte MD et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br. J. Cancer 2007; 96; 903-911.
31. Ghersi- Egea JF, Finnegan W, Chen JL, Fenstermacher JD. Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 1996; 75; 1271-1288.
32. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 2002; 19; 247-258.
33. van Kempen E, van Kamp I, Fischer P et al. Noise exposure and children's blood pressure and heart rate: the RANCH project. Occup. Environ. Med. 2006; 63; 632-639.
34. Schenk S, Hintermann E, Bilban M et al. Binding to EGF receptor of a laminin- 5 EGF- like fragment liberated during MMP- dependent mammary gland involution. J. Cell Biol. 2003; 161; 197-209.
35. Li CY, Zhang XL, Matthews EA et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006; 125; 20-34.
36. Rakha EA, El- Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple- negative breast cancer. Cancer 2007; 109; 25-32.
37. Cabernard E, Hulliger S. [Results of the modified dacryocystorhinostomie described by Werb (author's translation)]. Klin. Monatsbl. Augenheilkd. 1976; 168; 77-80.